XEROSTOMIA THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Global Xerostomia Therapeutics Market: Regional Insights

North America is expected to dominate the global xerostomia therapeutics market, followed by Europe during the forecast period. This is attributed to increase in awareness initiatives and increasing prevalence of xerostomia, and other dry mouth associated diseases such as Parkinson’s disease, diabetes, Sjogren’s syndrome, and HIV. For instance, Sjogren Syndrome Foundation in the U.S. was set up in 1985 with an objective of raising awareness and helping patients to manage xerostomia symptoms. Moreover, improved medical and healthcare infrastructure along with easily accessible health benefit compensation policies helped North American region to dominate over xerostomia therapeutics market of other geographical regions such as Asia-Pacific, Europe, etc.

In 2018, Prisyna, the oral care division of Synedgen, Inc., received the U.S. FDA approval for marketing Moisyn products that can manage the symptoms of xerostomia and also improves oral health of patients suffering from xerostomia. According to Prisyna, the clinical study results show that patients using Moisyn products experienced less pain while eating, less dryness while speaking, improved sleep, and an increase in the mouth sensation for better sense of taste. Moreover, in 2020, the University of Wisconsin Carbone Cancer Center received the IND (Investigational New Drug) license issued by U.S FDA to begin clinical trials on the first personalized immune activated cell therapy to treat radiotherapy related xerostomia. This cell therapy involves the patient’s own interferon-gamma activated marrow stromal cells.

Asia Pacific region is expected to witness an exponential growth owing to factors such as growing investments in healthcare, an increase in initiatives for xerostomia awareness, and rising prevalence of diseases, such as Alzheimer’s disease, hypertension, diabetes, HIV, cancer, and Parkinson’s disease that cause xerostomia. For instance, in 2020 World Health Organization estimated that dementia affected over 23 million people in Asia Pacific region and at this rate the numbers would triple in next 30 years. Asia Pacific is witnessing a significant increase in the prevalence of cancer due to an increase in the life expectancy in the region, which increases the chance of acquiring lifestyle related diseases such as cancer. For instance, in 2020 the WHO reported around 20 million prevalent cancer cases over a period of five years in the Asia Pacific region. Many countries such as China, India, etc. have managed to reduce the cost of chemotherapy and radiotherapy by encouraging local industries to manufacture cancer drugs. Reduced therapy costs, as well as a rise in the number of initiatives for creating awareness regarding xerostomia, lead to an increase in the adoption of chemotherapy and radiation therapy for cancer treatment.